Stay updated with breaking news from உயிரியல் ஏ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to sources, the government has signed the deal with domestic vaccine maker Biological-E for 300 million COVID-19 vaccine doses for 15 billion rupees (USD 205.62 million). ....
Read more about Govt to reserve 300 mn doses of Biological-E vaccine for August-December on Business Standard. The formulation, an RBD protein sub-unit vaccine, is currently undergoing Phase-3 trials ....
For this purpose, the Ministry of Health would be making an advance payment of ₹1,500 crore. The vaccine of Biological-E was currently undergoing Phase-3 clinical trial after it showed promising results in Phase 1 and 2 clinical trials. The RBD protein sub-unit vaccine is likely to be available in the next few months. “The proposal of M/s Biological-E was examined and recommended for approval after due diligence by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC),” the Ministry said. It added that the arrangement with the manufacturer is part of the wider endeavour of the government to encourage indigenous vaccine makers by providing them support in Research & Development and also financial support. ....
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement. ....
The RBD protein sub-unit vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement. ....